Antibiotics Market Research Report - Global Forecast till 2025

Antibiotics Market Research Report - Global Forecast till 2025

ID: MRFR/HC/6975-HCR | November, 2019 | Region: Global | 90 pages | Half-Cooked Research Reports

Market Forecast


Antibiotics Market is expected to cross USD 64,532 Million by 2025 at a CAGR of 4.8%.


Market Synopsis


Supportive government legislations, such as the implementation of the Generating Antibiotics Incentives Now (GAIN) Act in the US, are expected to accelerate the drug approval process in the antibiotics market.


GAIN Act facilitates the development of therapies against antibiotic-resistant pathogens. Thus, by this act, there is a rise in antibiotic approval in the US, with an average yearly approval rate more than double from 2000-2012 (0.8 approvals per year) to 2013-present (1.8 approvals per year). This creates a lucrative opportunity for the companies to enter the antibiotics market, thus fueling the market growth.


Market Influencers


An increasing number of antibiotics in the clinical development stage. In June 2019, approximately 42 new antibiotics with the ability to treat severe bacterial infections were in the clinical development stage. As a result, increasing the number of antibiotics would drive the demand for the global antibiotics market.


Market Drivers




  • Major companies undertook increasing efforts for the development of advanced antibiotics. According to the data published by the Pew Charitable Trust, in March 2016, clinical research was conducted for approximately 37 drug molecules within the US market. Majority of these molecules are in phase II clinical trials and are anticipated to launch in the near future, thus accelerating the growth of antibiotics market




  • Increasing approval of antibiotic drugs. In 2018, about 59 antibiotic drugs such as xospata, firdapse, and asparlas were approved by the US Food and Drug Administration (FDA).




  • The rise in the incidence of chronic and infectious diseases. There has been an increase in infectious disease rates. For instance, more than 17 million people were affected by contagious diseases globally.




  • Growing investment opportunities by biotech companies in research & development. As of June 2019, approximately 42 new antibiotics with the potential to treat severe bacterial infections are in clinical development




  • Development of generic drugs




Market Restraints



  • Increasing antibiotic-resistant infections. In the US, every year, approximately 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result of this.

  • Rise in drug approval costs


Segmentation


By Drug class




  • Cephalosporins: They are class of β-lactam antibiotics originally derived from Acremonium and are effective against a wide range of bacteria. They kill bacteria and have similar functions to that of penicillin.




  • Penicillin: Penicillin is used to treat bacterial infections. It is primarily used for the treatment of various diseases such as pneumonia, meningitis, endocarditis, and others.




  • Fluoroquinolones: Fluoroquinolones are used to treat respiratory and urinary tract infections (UTIs).




  • Macrolides: Macrolide antibiotics are effective in treating bacterial infections such as ear, nose, and throat infections, chest infections, skin infections, and mouth and dental infections.




  • Carbapenem: Fastest-growing segment. Growing incidence of UTIs pneumonia and bloodstream infections are expected to increase the usage of carbapenems class of antibiotics. In 2016, the consumption of carbapenems in Europe was approximately 0.05 defined daily doses (DDD) per 1,000 people per day.




  • Aminoglycosides: Aminoglycosides are a class of antibiotics that are used mainly in the treatment of aerobic gram-negative bacilli infections.




  • Sulfonamides: Contains sulfonamide chemical group. This class of antibiotics is used in diabetes and pain relief.




  • Others: Others include tetracyclines, monoclonal antibodies, imidazoles, and lincosamides.




By Spectrum of Activity




  • Broad-spectrum Antibiotic: Largest segment. Broad-Spectrum antibiotics act against a wide range of diseases, which in turn helps to fight against antimicrobial resistance, thus driving the growth of this segment. Examples include aminoglycosides, cephalosporins, and quinolones.




  • Narrow-spectrum Antibiotic: Narrow-spectrum antibiotics are active against selected types of bacteria. Examples include macrolides and vancomycin.




By Drug Origin




  • Natural: Derived from natural sources such as plant extracts and essential oils that have antibiotic properties.




  • Semi-synthetic: Fastest-growing segment. Semi-synthetic antibiotics are the derivatives of natural antibiotics with somewhat different but useful characteristics. They can act against bacteria that are resistant to the original compound, have a broad-spectrum of activity, and cause fewer side-effects. An example of semisynthetic includes ampicillin drug.




  • Synthetic: Related to natural antibiotics. It includes the quinolone class of antibiotics.




By End-User




  • Hospitals & Clinics: The largest segment, a majority of treatment and procedures are carried out in hospitals. In 2016, the average consumption of antibiotics for systemic use in hospitals was 2.1 defined daily doses (DDD) per 1,000 people per day.




  • Research Organizations: They encourage the research & development of new antimicrobial drugs and diagnostics, thus would drive the growth of the market. Global Antibiotic Research & Development Partnership address global public health needs by delivering and developing new or improved antibiotic treatments.




  • Others: Others include academic institutes, nursing homes, and emergency care centers.




By Region




  • Americas: The largest regional market. Rising growth in the pharmaceutical sector, increasing adoption of antibiotics, are the significant factors that would drive the growth of the antibiotics market in this region.




  • Europe: Rising consumption of antibiotics, high prevalence of infectious diseases, increase in usage of generic medicines. These factors are anticipated to drive the growth of the antibiotics market in this region.




  • Asia-Pacific: The fastest-growing regional market in antibiotics owing to the rising consumption of antibiotics, an increase in the sale of over the counter (OTC) drugs, and the easy availability of drugs.




  • Middle East & Africa: Increasing healthcare expenditure and rising consumption of antibiotics would drive the demand for the antibiotics market in this region.




Key Players



  • Pfizer Inc. (US)                                              

  • Johnson & Johnson Services, Inc. (US)                                 

  • Abbott Laboratories (US)                          

  • GlaxoSmithKline PLC (UK)

  • Sanofi (France)

  • Novartis AG (Switzerland)

  • Bayer AG (Germany)                                  

  • Bristol-Myers Squibb Company (US)                                    

  • Eli Lilly and Company (US)                        

  • Astellas Pharma Inc. (Japan)                                    

  • Merck & Co., Inc. (US)                                

  •  F. Hoffmann-La Roche Ltd (Switzerland)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. Regulatory Framework

6. GLOBAL ANTIBIOTICS MARKET, BY DRUG CLASS

6.1. Overview

6.2. Cephalosporins

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.3. Penicillin

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.4. Fluoroquinolones

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.5. Macrolides

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.6. Carbapenem

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.7. Aminoglycosides

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.8. Sulfonamides

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

6.9. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7. GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

7.1. Overview

7.2. Broad-Spectrum Antibiotic

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

7.3. Narrow-Spectrum Antibiotic

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8. GLOBAL ANTIBIOTICS MARKET, BY DRUG ORIGIN

8.1. Overview

8.2. Natural

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.3. Semi-Synthetic

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

8.4. Synthetic

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9. GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

9.1. Overview

9.2. Oral

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.3. Intravenous

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

9.4. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

10. GLOBAL ANTIBIOTICS MARKET, BY END USER

10.1. Overview

10.2. Hospitals & Clinics

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

10.3. Research Organizations

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

10.4. Others

Market Estimates & Forecast, by Region, 2019–2025

Market Estimates & Forecast, by Country, 2019–2025

11. GLOBAL ANTIBIOTICS MARKET, BY REGION

11.1. Overview

11.2. Americas

11.2.1. North America

11.2.1.1. US

11.2.1.2. Canada

11.2.2. Latin America

11.3. Europe

11.3.1. Western Europe

11.3.1.1. Germany

11.3.1.2. France

11.3.1.3. Italy

11.3.1.4. Spain

11.3.1.5. UK

11.3.1.6. Rest of Western Europe

11.3.2. Eastern Europe

11.4. Asia-Pacific

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. Australia

11.4.5. South Korea

11.4.6. Rest of Asia-Pacific

11.5. Middle East & Africa

11.5.1. Middle East

11.5.2. Africa

12. COMPANY LANDSCAPE

12.1.1. Overview

12.1.2. Competitive Analysis

13. COMPANY PROFILES

13.1. Pfizer Inc.

13.1.1. Company Overview

13.1.2. Product Overview

13.1.3. Financial Overview

13.1.4. Key Developments

13.1.5. SWOT Analysis

13.1.6. Key Strategies

13.2. Johnson & Johnson Services, Inc.

13.2.1. Company Overview

13.2.2. Product Overview

13.2.3. Financial Overview

13.2.4. Key Developments

13.2.5. SWOT Analysis

13.2.6. Key Strategies

13.3. Abbott Laboratories

13.3.1. Company Overview

13.3.2. Product Overview

13.3.3. Financial Overview

13.3.4. Key Developments

13.3.5. SWOT Analysis

13.3.6. Key Strategies

13.4. GlaxoSmithKline PLC

13.4.1. Company Overview

13.4.2. Product Overview

13.4.3. Financial Overview

13.4.4. Key Developments

13.4.5. SWOT Analysis

13.4.6. Key Strategies

13.5. Sanofi

13.5.1. Company Overview

13.5.2. Product Overview

13.5.3. Financial Overview

13.5.4. Key Developments

13.5.5. SWOT Analysis

13.5.6. Key Strategies

13.6. Novartis AG

13.6.1. Company Overview

13.6.2. Product Overview

13.6.3. Financial Overview

13.6.4. Key Developments

13.6.5. SWOT Analysis

13.6.6. Key Strategies

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Overview

13.7.3. Financial Overview

13.7.4. Key Developments

13.7.5. SWOT Analysis

13.7.6. Key Strategies

13.8. Bristol-Myers Squibb Company

13.8.1. Company Overview

13.8.2. Product Overview

13.8.3. Financial Overview

13.8.4. Key Developments

13.8.5. SWOT Analysis

13.8.6. Key Strategies

13.9. Eli Lilly and Company

13.9.1. Company Overview

13.9.2. Product Overview

13.9.3. Financial Overview

13.9.4. Key Developments

13.9.5. SWOT Analysis

13.9.6. Key Strategies

13.10. Astellas Pharma Inc.

13.10.1. Company Overview

13.10.2. Product Overview

13.10.3. Financial Overview

13.10.4. Key Developments

13.10.5. SWOT Analysis

13.10.6. Key Strategies

13.11. Merck & Co., Inc.

13.11.1. Company Overview

13.11.2. Product Overview

13.11.3. Financial Overview

13.11.4. Key Developments

13.11.5. SWOT Analysis

13.11.6. Key Strategies

13.12. F. Hoffmann-La Roche Ltd

13.12.1. Company Overview

13.12.2. Product Overview

13.12.3. Financial Overview

13.12.4. Key Developments

13.12.5. SWOT Analysis

13.12.6. Key Strategies

14. APPENDIX

14.1. References

14.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL ANTIBIOTICS MARKET SYNOPSIS, 2019–2025

TABLE 2 GLOBAL ANTIBIOTICS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)

TABLE 3 GLOBAL ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 4 GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 5 GLOBAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 6 GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 7 GLOBAL ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 8 GLOBAL ANTIBIOTICS MARKET, BY REGION, 2019–2025 (USD MILLION)

TABLE 9 NORTH AMERICA: ANTIBIOTICS, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 10 NORTH AMERICA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 11 NORTH AMERICA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 12 NORTH AMERICA: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 13 NORTH AMERICA: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 14 US: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 15 US: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 16 US: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 17 US: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 18 US: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 19 CANADA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 20 CANADA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 21 CANADA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 22 CANADA: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 23 CANADA: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 24 LATIN AMERICA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 25 LATIN AMERICA: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 26 LATIN AMERICA: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 27 LATIN AMERICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 28 LATIN AMERICA ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 29 EUROPE: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 30 EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 31 EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 32 EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 33 EUROPE: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 34 WESTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 35 WESTERN EUROPE: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 36 WESTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 37 WESTERN EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 38 WESTERN EUROPE: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 39 EASTERN EUROPE ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 40 EASTERN EUROPE: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 41 EASTERN EUROPE: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 42 EASTERN EUROPE: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 43 EASTERN EUROPE: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 44 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 45 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 46 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 47 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 48 ASIA-PACIFIC: ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA: ANTIBIOTICS MARKET, BY DRUG CLASS, 2019–2025 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2019–2025 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2019–2025 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA ANTIBIOTICS MARKET, BY END USER, 2019–2025 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTIBIOTICS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTIBIOTICS MARKET

FIGURE 4 GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUG CLASS, 2018 (%)

FIGURE 5 GLOBAL ANTIBIOTICS MARKET SHARE, BY SPECTRUM OF ACTIVITY, 2018 (%)

FIGURE 6 GLOBAL ANTIBIOTICS MARKET SHARE, BY DRUG ORIGIN, 2018 (%)

FIGURE 7 GLOBAL ANTIBIOTICS MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018 (%)

FIGURE 8 GLOBAL ANTIBIOTICS MARKET SHARE, BY END USER (%)

FIGURE 9 GLOBAL ANTIBIOTICS MARKET SHARE, BY REGION, 2018 (%)

FIGURE 10 AMERICAS: ANTIBIOTICS MARKET SHARE BY REGION, 2018 (%)

FIGURE 11 NORTH AMERICA: ANTIBIOTICS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 12 EUROPE: ANTIBIOTICS MARKET SHARE, BY REGION, 2018 (%)

FIGURE 13 WESTERN EUROPE: ANTIBIOTICS OR MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 14 ASIA-PACIFIC: ANTIBIOTICS MARKET SHARE, BY REGION, 2018 (%)

FIGURE 15 MIDDLE EAST & AFRICA: ANTIBIOTICS MARKET SHARE, BY COUNTRY, 2018 (%)

FIGURE 16 GLOBAL ANTIBIOTICS MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

FIGURE 17 PFIZER INC.: KEY FINANCIALS

FIGURE 18 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 19 PFIZER INC.: REGIONAL REVENUE

FIGURE 20 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 21 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 22 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 23 ABBOTT LABORATORIES: KEY FINANCIALS

FIGURE 24 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 25 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 SANOFI: KEY FINANCIALS

FIGURE 30 SANOFI: SEGMENTAL REVENUE

FIGURE 31 SANOFI: REGIONAL REVENUE

FIGURE 32 NOVARTIS AG: KEY FINANCIALS

FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 34 NOVARTIS AG: REGIONAL REVENUE

FIGURE 35 BAYER AG: KEY FINANCIALS

FIGURE 36 BAYER AG: SEGMENTAL REVENUE

FIGURE 37 BAYER AG: REGIONAL REVENUE

FIGURE 38 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 39 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 41 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 42 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 43 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 44 ASTELLAS PHARMA INC..: KEY FINANCIALS

FIGURE 45 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE

FIGURE 46 ASTELLAS PHARMA INC.: REGIONAL REVENUE

FIGURE 47 MERCK & CO., INC.: KEY FINANCIALS

FIGURE 48 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 49 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 50 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 51 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 52 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Antibiotics Market